Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Glaxo Wellcome

This article was originally published in The Tan Sheet

Executive Summary

Glaxo Wellcome: Appointing a U.S. chief operating officer is a priority for Glaxo Wellcome CEO Robert Ingram following his elevation to the chief exec spot, announced Oct. 28. Ingram keeps his position as head of the U.S. operating division of Glaxo (Glaxo Wellcome, Inc.) but will name a new chief operating officer as soon as possible. The lack of an immediate successor to handle the day-to-day operations of the company highlights the impression of suddenness surrounding Glaxo's announcement of Ingram's promotion. Ingram's appointment as CEO comes just five months after Sean Lance was named chief operating officer and CEO-designate of Glaxo Wellcome plc. Lance, "as a result of this decision, will be leaving the company after 12 years of outstanding service," Glaxo says. Lance's departure is not related to differences over strategic direction or to the performance of the company, Glaxo maintains...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel